101 related articles for article (PubMed ID: 20211915)
1. The challenge of follow-on biologics for treatment of multiple sclerosis.
Rivera VM
Neurology; 2010 Mar; 74(10):864. PubMed ID: 20211915
[No Abstract] [Full Text] [Related]
2. The challenge of follow-on biologics for treatment of multiple sclerosis.
Reingold SC; Steiner JP; Polman CH; Cohen JA; Freedman MS; Kappos L; Thompson AJ; Wolinsky JS
Neurology; 2009 Aug; 73(7):552-9. PubMed ID: 19687456
[TBL] [Abstract][Full Text] [Related]
3. Using Medicare administrative data to conduct postmarketing surveillance of follow-on biologics: issues and opportunities.
DiMartino LD; Curtis LH; Williams RL; Abernethy DR; Schulman KA
Food Drug Law J; 2008; 63(4):891-900. PubMed ID: 19601387
[No Abstract] [Full Text] [Related]
4. Identity of interferon-beta1a product in multiple sclerosis study.
Wolf WW
Ann Neurol; 1997 Apr; 41(4):560. PubMed ID: 9124816
[No Abstract] [Full Text] [Related]
5. [Interferon-beta in the treatment of multiple sclerosis].
Panelius M; Salonen R; Ruutiainen J
Duodecim; 1995; 111(7):587-9. PubMed ID: 8681813
[No Abstract] [Full Text] [Related]
6. Anti-interferon antibodies: surprises and lessons.
Pachner A
Lancet Neurol; 2004 Sep; 3(9):515. PubMed ID: 15324716
[No Abstract] [Full Text] [Related]
7. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
8. [Interferon therapy of multiple sclerosis].
Jensen D
Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3142-5. PubMed ID: 10522481
[TBL] [Abstract][Full Text] [Related]
9. [Beta-interferon and multiple sclerosis].
Clanet M
Rev Neurol (Paris); 1993; 149(8-9):443-4. PubMed ID: 8009140
[No Abstract] [Full Text] [Related]
10. Berlex continues legal challenge to FDA over MS drug.
Glaser V
Nat Biotechnol; 1996 Jul; 14(7):811-2. PubMed ID: 9630997
[No Abstract] [Full Text] [Related]
11. Interferon beta in the treatment of multiple sclerosis--closing remarks.
Kappos L
Mult Scler; 1995; 1 Suppl 1():S64-6. PubMed ID: 9345403
[No Abstract] [Full Text] [Related]
12. Interferon beta in multiple sclerosis. Relapses deserve treatment.
Cardy P
BMJ; 1997 Feb; 314(7080):602. PubMed ID: 9055732
[No Abstract] [Full Text] [Related]
13. Interferon beta in multiple sclerosis. Interferon beta reduces overall relapse rate by one third.
Napier JC
BMJ; 1997 Feb; 314(7080):601. PubMed ID: 9055729
[No Abstract] [Full Text] [Related]
14. [Interferon-beta-1b treatment of disseminated sclerosis].
Sørensen S
Ugeskr Laeger; 1997 Feb; 159(6):779-84. PubMed ID: 9045474
[No Abstract] [Full Text] [Related]
15. Beta-Interferon and multiple sclerosis: not a final solution to the problem.
Compston A
Br J Hosp Med; 1995 Jun 7-20; 53(11):547-9, 551, 553. PubMed ID: 7655750
[No Abstract] [Full Text] [Related]
16. Interferon beta in multiple sclerosis. Current policy is sensible.
Price C
BMJ; 1997 Feb; 314(7080):600-1. PubMed ID: 9055728
[No Abstract] [Full Text] [Related]
17. [Clinical testing of the treatment effect of interferon-beta Ia and Ib in multiple sclerosis].
de Haan RJ; Polman CH
Ned Tijdschr Geneeskd; 1996 Nov; 140(44):2168-71. PubMed ID: 8984352
[No Abstract] [Full Text] [Related]
18. Interferon beta in multiple sclerosis. Some form of compromise must be accepted.
Peltola J; Keranen T
BMJ; 1997 Feb; 314(7080):602. PubMed ID: 9055733
[No Abstract] [Full Text] [Related]
19. Interferon beta-1A for relapsing multiple sclerosis.
Med Lett Drugs Ther; 1996 Jul; 38(979):63-4. PubMed ID: 8692073
[No Abstract] [Full Text] [Related]
20. [Treatment of multiple sclerosis using recombinant interferon-beta].
Polman CH; Barkhof F; van Loenen AC; Lucas CJ; Koetsier JC
Ned Tijdschr Geneeskd; 1994 Jan; 138(1):7-10. PubMed ID: 8289963
[No Abstract] [Full Text] [Related]
[Next] [New Search]
